Image 1 of 1
Image 1 of 1
Image 1 of 1
Image 1 of 1
Zepbound (tirzepatide) is an FDA-approved, once-weekly subcutaneous prescription injection manufactured by Eli Lilly and Company. It is indicated for chronic weight management in adults with obesity (BMI of 30 or higher) or adults who are overweight (BMI of 27 or higher) with at least one weight-related medical condition. It is also approved to treat moderate to severe obstructive sleep apnea (OSA) in adults with obesity
Zepbound (tirzepatide) is an FDA-approved, once-weekly subcutaneous prescription injection manufactured by Eli Lilly and Company. It is indicated for chronic weight management in adults with obesity (BMI of 30 or higher) or adults who are overweight (BMI of 27 or higher) with at least one weight-related medical condition. It is also approved to treat moderate to severe obstructive sleep apnea (OSA) in adults with obesity